Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned unit, Fosun Pharma (Xuzhou) Co., Ltd., has received National Medical Products Administration approval for Venlafaxine Hydrochloride Sustained-release Tablets (75 mg). The product is indicated for the treatment of depression—including depression with anxiety—and generalized anxiety disorder.

Classified as a Class 3 chemical medicine, the tablet is the Group’s proprietary development. Cumulative R&D investment reached approximately RMB7.68 million as of April 2026.

Market data from IQVIA CHPA show that domestic sales of all Venlafaxine Hydrochloride formulations in mainland China totaled about RMB584 million in 2025, underscoring the product’s commercial potential. Management stated that the new approval expands the Group’s central-nervous-system portfolio, while cautioning that actual sales will depend on market demand, competitive dynamics, and distribution capabilities.

The approval is formalized under drug registration number Guo Yao Zhun Zi H202641902. The board issued the announcement on 8 May 2026.